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provides an excellent LC. However, despite good local 
control we observed a crude distant metastasis rate of 25% in 
N2 disease, suggesting a need for novel chemotherapeutic 
approaches to improve systemic control in these patients. OS 
was significantly influenced by T staging (p=0.035), 
suggesting the need for dose escalation in patients with 
higher T-stage (cT3-T4). Therefore, further studies are 
warranted to evaluate if dose escalation to both gross tumor 
and areas of potential nodal spread can improve LC and OS. 
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Purpose/Objective: Intra luminal brachytherapy (ILBT) is 
utilised for oesophageal cancer as a palliative treatment with 
the aim to improve and maintain patients’ swallowing 
function and delaying or avoiding the need for an 
endoluminal oesophageal stent. It is utilised as a boost 
treatment following external beam radiotherapy in patients’ 
deemed unsuitable for definitive chemoradiation or high dose 
external beam treatments; or as salvage treatment for those 
with relapsed disease more than 6 months from external 
beam treatment.Treatment was delivered either as a single 
8Gy dose to the PTV or 14-16 Gy in 2 fractions a maximum of 
1 week apart. In this retrospective analysis, we evaluate the 
outcomes of patients treated with ILBT in West Yorkshire 
over a 4 year period.  
Materials and Methods: Information collected from entries in 
the Leeds oesophageal brachytherapy database and patient 
pathway manager (clinical data software). Data on basic 
patient/tumour demographics, date of treatment, 
dose/fractionation schedule of treatment, brachytherapy 
dosimetric data, toxicity profile, swallowing assessment 
before and after treatment and date of subsequent 
oesophageal stent (if needed) was reviewed.  
All ILBT treatments were 3D CT conformal planned  
Results: A total of 33 patients have been treated between 
April 2010 and August 2014. The median performance status 
was one. 21patients (64%) patients had a single treatment. 
Most treatments (76 %) were given as boost following 30Gy in 
10 fractions of external beam radiotherapy. 27% of patients 
required subsequent oesophageal stent insertion for 
palliation of critical dysphagia. The median overall survival 
was 211 days whilst the median stent free survival was 204 
days. 6% of patients had documented grade 3 RTOG toxicity, 
related to dysphagia. There were no treatment related 
bleeding or perforation events. The median PTV volume was 
38.3cm3 with the median maximum diameter for each PTV 
38.0mm. Mean PTV V100 was 81.9%(+/-15.2%, 1SD), and V200 
of 38.1%(+/- 13.2%, 1SD). Mean PTV D90 was 6.4Gy(+/- 
1.5Gy, 1SD) and Mean GTV D90 was 7.2Gy(+/- 1.3%, 1SD) for 
each fraction. The spinal cord mean D2cc (maximum dose for 
2cc volume of spinal cord) was 1.1Gy(+/- 0.5Gy, 1SD) whilst 
the mean D0.1cc was 1. 5Gy(+/- 0.6Gy, 1Sd). 
Conclusions: Intra luminal oesophageal brachytherapy is a 
safe and effective method of delivering palliative 
radiotherapy for patients with oesophageal cancer where 
other radical treatments are deemed inappropriate. It is well 
tolerated and can delay or eliminate the need for 
oesophageal stents for symptomatic dysphagia. Further study 
in to the role of using sequential ILBT with removable stents 
to maintain swallowing function is required.  
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Purpose/Objective: Standard treatment for locally advanced 
rectal cancer is neoadjuvant fluoropyrimidine-based 
chemoradiotherapy (CRT) followed by total mesorectal 
excision. Research has been focused on intensifying 
neoadjuvant treatment. This systematic review evaluated 
Phase II treatment intensification trials. 
Materials and Methods: A systematic search of the PubMed, 
EMBASE, MEDLINE and the Cochrane Library databases was 
performed from January 2004 to September 2014 for all 
published Phase II trials of neoadjuvant treatment 
intensification in locally advanced rectal cancer. Eighty-one 
eligible Phase II trials were identified from 474 articles. For 
each trial, clinical, methodological and statistical 
components were assessed. 
Results: Ninety-one experimental arms from 81 trials were 
identified. Median number of patients recruited per trial was 
50 (range: 8–279) over a median recruitment period of 26 
months (range: 4–108). Eighty-three arms studied CRT 
intensification: 36(36.6%) additional cytotoxic, 10(11.0%) 
additional biological agent, 3(3.3%) additional radiosensitiser, 
16(17.6%) radiotherapy dose intensification, and 18(19.8%) a 
combination of agents. Neoadjuvant chemotherapy was 
added in 22 experimental arms (14 arms alongside CRT 
intensification): 7(7.7%) additional cytotoxic, 1(1.1%) 
additional biological agent and 6(6.6%) a combination of 
agents. 
Only nine trials were randomised of which five had a 
standard control arm. Twenty studies did not report a 
sample size calculation and only 44(54.3%) studies stated 
their statistical trial design. Fifteen differently defined 
primary endpoints were stated in 73 studies. Seventy-six 
trials recruited both AJCC stage II and III disease. MRI local 
staging was mandated in 35 trials while the circumferential 
resection margin was assessed in only 10 trials. Only 31 of the 
81 studies were rated to have a good overall statistical design 
and compliance. No meta-analysis could be performed due to 
trial heterogeneity. 
Conclusions: The very small number of randomised phase II 
trials, the lack of agreement regarding useful primary end 
points and the poor clinical trial design quality are major 
concerns. These factors are likely to be a major contributor 
